Nexalin Technology, Inc. (NXL)

US — Healthcare Sector
Peers: AIMDW  ELMD  ARMM  SRDX  BJDX  INVO  MOTS  IRIX  AZYO  AIMD  LNSR  OSA  LIVN  KIDS  MODD  NPCE  SSKN  NMRD 

Automate Your Wheel Strategy on NXL

With Tiblio's Option Bot, you can configure your own wheel strategy including NXL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NXL
  • Rev/Share 0.0098
  • Book/Share 0.1747
  • PB 5.9516
  • Debt/Equity 0.0
  • CurrentRatio 4.5596
  • ROIC -3.7363

 

  • MktCap 18114646.0
  • FreeCF/Share -0.3425
  • PFCF -3.9749
  • PE -1.6178
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -2.7796

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3
NXL
Published: May 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.m. ET. Attendees will gain an inside look at Nexalin's game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology.

Read More
image for news Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
NXL
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and other offering expenses.

Read More
image for news Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
NXL
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company initiates formal regulatory engagement on trial design for Alzheimer's, dementia, and MCI indications Company initiates formal regulatory engagement on trial design for Alzheimer's, dementia, and MCI indications

Read More
image for news Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
NXL
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral

AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™

Read More
image for news Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
NXL
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOUSTON, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced its support for the Health Tech Investment Act (S. 1399) — bipartisan legislation introduced in the United States Senate that would expand Medicare reimbursement opportunities for FDA-cleared or approved medical devices that incorporate artificial intelligence (AI) or machine learning.

Read More
image for news Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
NXL
Published: April 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

Patent Approval Reinforces Nexalin's Leadership in Non-Invasive Brain Stimulation for Addiction Treatment Patent Approval Reinforces Nexalin's Leadership in Non-Invasive Brain Stimulation for Addiction Treatment

Read More
image for news Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3
NXL
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET.

Read More
image for news Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

About Nexalin Technology, Inc. (NXL)

  • IPO Date 2022-09-16
  • Website https://www.nexalin.com
  • Industry Medical - Devices
  • CEO Mr. Mark White
  • Employees 6

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.